



10 August 2022
EMA/613778/2022

Cetrotide (cetorelix acetate) 0.25 mg powder and solvent for solution for infusion	
Indication	Cetrotide is used to prevent premature ovulation (early release of eggs from the ovary). It is given to women having ovarian stimulation (fertility treatment where the ovaries are stimulated to produce more eggs).
Reason for shortage	<p>A technical issue at the main manufacturing site for Cetrotide resulted in closure of the site between December 2021 and March 2022. This has led to reductions and delays in the supply of the medicine which may affect certain Member States until the end of 2022.</p> <p>The quality of the manufactured and released product batches is not affected by these technical problems.</p>
Member States affected¹	Supply disruptions affect EU/EEA Member States where Cetrotide is marketed (Belgium, Bulgaria, Cyprus, Greece, Hungary, Ireland, Latvia, Lithuania, Estonia, Luxembourg, Malta, Netherlands, Poland, Portugal and Romania).
Information for healthcare professionals	<ul style="list-style-type: none">• Technical problems at the main product manufacturing site for Cetrotide have led to a shortage.• Patients should not be started on a cycle with Cetrotide. Please liaise with the marketing authorisation holder (Merck) contact point for further information. In the absence of Cetrotide, you may use a suitable alternative available on the market.

¹ This information may change. For up-to-date information about the status of a medicine shortage in a particular Member State, contact the national competent authority.



Cetrotide (cetorelix acetate)

0.25 mg powder and solvent for solution for infusion

	<ul style="list-style-type: none">• A letter (DHPC) regarding this issue was sent out to healthcare professionals and can also be found on the EMA website.• Additional advice may be available from the national competent authority.
Information for patients	<ul style="list-style-type: none">• Technical problems at the manufacturing site where Cetrotide is produced have resulted in a product shortage.• During the shortage period, it is recommended that patients do not start treatment with this medicine.• Instead, patients can be treated with a suitable alternative available on the market.• Patients who have any questions should speak to their doctor or pharmacist.• Additional advice may be available from the national competent authority.
Status	Ongoing